1st Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Waste (hazardous/solid/interstate/nuclear) WAS

Communication to Environmental Protection Agency regarding addition of pharmaceuticals to universal waste rule.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
MORGAN HANSON —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: White House Office; Centers For Medicare and Medicaid Services (CMS); Environmental Protection Agency (EPA); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Drug Enforcement Administration (DEA); Health & Human Services, Dept of (HHS)

Health Issues HCR

HR 1, American Recovery and Reinvestment Act, Title XIII, Health information technology provisions. FDA appropriations FY09 & FY10. Communication re: confirmation of Secretary-Designate Daschle, and Sebelius. Communication to White House Office regarding health care reform. Statement to Senate Finance Committee on workforce and health care reform. Health care reform (no bill #). Letter to Office of the Nat. Coordinator for Health Information Technology regarding Standards Committee appointment.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
MORGAN HANSON —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); Drug Enforcement Administration (DEA); White House Office; Food & Drug Administration (FDA)

Bills named: H.R. 1 (111th)

Medicare/Medicaid MMM

Communication and meetings with CMS staff regarding compendia recognition. Presentation and written testimony before CMS Ambulatory Payment Classification Panel regarding pharmacy overhead. Communication to CMS re: nomination to APC panel. Comments to CMS re: 2010 call letter concerning Part D medication therapy management programs. Communication to CMS regarding payment policy for outpatient anticoagulation services.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
MORGAN HANSON —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: Food & Drug Administration (FDA); White House Office; Drug Enforcement Administration (DEA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS)

Pharmacy PHA

Communication seeking withdrawal of propxyphene from the market. Communication re: experimental study of consumer reporting of side effects as part of direct-to-consumer advertising. Communication re: evaluation and usefulness of consumer medication information. Communication re: FDA's Sentinal Initiative to monitor medical product safety. Comments on disposal of controlled substances.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
MORGAN HANSON —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Drug Enforcement Administration (DEA); Food & Drug Administration (FDA); Environmental Protection Agency (EPA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.